Bristol-Myers Squibb Co (NYSE:BMY) shares have lost about 36% over the past one year. The stock is getting clobbered amid fears of sales declines following patent expirations. Bristol-Myers Squibb Co's (NYSE:BMY) cancer drug Revlimid has seen severe sales declines after it went off-patent in 2022. Bristol-Myers Squibb Co's (NYSE:BMY) anti-stroke drug Eliquis is going off-patent in 2026. To offset the potential declines, Bristol-Myers Squibb Co (NYSE:BMY) is going on a buying spree, acquiring smaller companies to expand its portfolio.